OTHER PUBLICATIONS & ABSTRACTS
Other Data
Evidence / Other
FLEX Study Update, Alberty et al, SABCS 2023 Abstract
SABCS 2023, PO3-02-02 Authors: JJ Alberty-Oller, et al.
Read MoreComparison of genomic test scores and CT Indications – SABCS 2023
SABCS 2023 Author: Vidal, Singh et al.
Read MoreNurse Navigators’ Role in Personalized ESBC Treatment, A Case Study
Publication: Journal of Oncology Navigation & Survivorship, Nov 2023, Vol 14 Authors: Jo Weathers, RN, BSN, OCN, ONN-CG; Jane Baker, RN, MSN; Victoria Poillucci, DNP, MEd, ACNP-BC; Christina Z. Page, AOCNP, AGPCNP-BC
Read MoreTRAIN 2 Trial: BluePrint predicts response to neoadjuvant pertuzumab in HER2-positive
Breast Cancer Research 25, Article Number: 71 (2023) Authors: Liefaard et al.
Read MoreFLEX: 30K Full Transcriptome, Real-World Evidence Database for Early-Stage Breast Cancer, and Investigator-Initiated Protocols
Publication: ASCO 2023, Abstract #TPS621 Authors: Eric A. Brown1; Linsey P. Gold1; Carl R. Gray2; Douglas K. Marks3; Vibha T. Thomas4; Alfredo A. Santillan5; Cynthia Ma6; Ciera Singleton7; William Audeh7; on behalf of the FLEX Investigators Group 1. Comprehensive Breast Care, Troy, MI; 2. Utah Hem Onc, Ogden, UT; 3. Perlmutter Cancer Center, NYU Langone Health, New York, NY; 4. Texas Oncology-Flower Mound, Flower Mound, TX; 5. Texas Oncology PA, San Antonio, TX; 6. Washington University School of Medicine, St. Louis, MO; 7. Agendia Inc., Irvine, CA.
Read MoreImpact of race on BluePrint genomic subtyping in HER2+ breast cancer
Publication: ASCO 2023, Abstract #TPS621 Authors: Eric A. Brown1; Linsey P. Gold1; Carl R. Gray2; Douglas K. Marks3; Vibha T. Thomas4; Alfredo A. Santillan5; Cynthia Ma6; Ciera Singleton7; William Audeh7; on behalf of the FLEX Investigators Group 1. Comprehensive Breast Care, Troy, MI; 2. Utah Hem Onc, Ogden, UT; 3. Perlmutter Cancer Center, NYU Langone Health, New York, NY; 4. Texas Oncology-Flower Mound, Flower Mound, TX; 5. Texas Oncology PA, San Antonio, TX; 6. Washington University School of Medicine, St. Louis, MO; 7. Agendia Inc., Irvine, CA.
Read MoreImPrint immune signature in 10,000 early stage breast cancer patients from FLEX Study
SABCS 2022, Poster ID: PD9-08 Authors: Brufsky et al.
Read More
